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Background
Imatinib, given concurrently or alternating with chemotherapy, has improved the
response and survival of patients with Philadelphia chromosome-positive acute lym-
phoblastic leukemia (Ph+ ALL) but relapses are still frequent. The aim of this study was to
evaluate the feasibility and results of giving imatinib concurrently with intensive
chemotherapy, stem cell transplantation and post-transplant imatinib maintenance thera-
py in patients with newly diagnosed Ph+ ALL.
Design and Methods
This was a phase II study of patients with newly diagnosed Ph+ ALL given standard
chemotherapy, together with imatinib (400 mg/day) until stem cell transplantation, fol-
lowed by imatinib maintenance therapy for all patients regardless of the molecular status
of the disease. 
Results
Of the 30 patients included, 27 (90%) achieved complete remission, one was resistant to
treatment and two died during induction therapy. The percentages of major and complete
molecular responses were 86% and 21% after induction, and 81% and 65% after consoli-
dation, respectively. Similar results were observed assessing minimal residual disease by
flow cytometry. Of the 27 patients who achieved complete remission, 21 underwent stem
cell transplantation (16  allogeneic, 5 autologous). Imatinib (400 mg/day) could be adminis-
tered after transplantation for a median of 3.9 months in 12 patients, although it was inter-
rupted in 10 patients (in 2 cases because of side effects of the drug). Nine patients relapsed,
four before and five after stem cell transplantation and eight patients died of transplant-
related causes. With a median follow-up of 4.1 years, the probabilities (95% CI) of disease-
free and overall survival were 30% (15% to 45%) and 30% (16% to 45%), respectively. 
Conclusions
These results confirm that imatinib is an effective first-line treatment for adult Ph+ ALL
when given concurrently with chemotherapy, making stem cell transplantation feasible in
a high proportion of patients. However, post-transplantation imatinib administration was
limited, mainly because of transplantation-derived complications rather than drug-specif-
ic toxicity. 
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Introduction
The Philadelphia chromosome is the most frequent sin-
gle recurrent cytogenetic abnormality in acute lymphoblas-
tic leukemia (ALL) in adults and together with the t(4;11)
rearrangement is the most adverse prognostic factor in
these patients.1,2 The Philadelphia chromosome carries the
BCR-ABL fusion gene, which encodes the p190BCR-ABL
and p210BCR-ABL oncoproteins that are targeted by the
tyrosine kinase inhibitor, imatinib.
Concurrent or alternating use of imatinib together with
intensive chemotherapy for remission induction and con-
solidation is associated with a high frequency of morpho-
logic (95%-100%) and molecular (50%) complete remis-
sions3-8 in young adults with Philadelphia chromosome-
positive (Ph+) ALL. These features have translated into a sig-
nificantly higher probability of survival than that obtained
in historical controls with similar chemotherapy schedules
without imatinib. Consequently, the combination of ima-
tinib and chemotherapy is currently considered the stan-
dard treatment for Ph+ ALL.9
In young patients with a histocompatible donor, allo-
geneic stem cell transplantation (SCT) is usually recom-
mended in first complete remission when feasible, espe-
cially in patients with no residual disease or minimal resid-
ual disease (MRD); alternatively, the transplant can be car-
ried out immediately after detection of disease at the
molecular level. However, with prolonged follow-up a sub-
stantial proportion of young patients and practically all eld-
erly patients relapse.10-12 Some of the relapses are late, mak-
ing careful molecular follow-up of these patients mandato-
ry.
There is little information on the feasibility and efficacy
of giving imatinib as maintenance therapy to prevent
relapse after SCT in patients already treated with imatinib
and chemotherapy prior to the transplant. Uncontrolled
studies13 and ongoing clinical trials14 indicate that the use of
imatinib is feasible, with a low relapse rate and an accept-
able transplant-related mortality, but problems with tolera-
bility may lead to early discontinuation of imatinib or limit
the intensity of the dose that can be given to some patients.
On the other hand, whether this drug needs to be given to
patients without residual disease after SCT, the optimal
duration of imatinib treatment and the feasibility and the
efficacy of combinations of imatinib with other agents as
maintenance therapy are all unknown.9
We undertook a prospective phase II study to evaluate
the efficacy of concurrent administration of imatinib and
intensive chemotherapy during remission induction and
consolidation, and the feasibility and efficacy of imatinib




Patients up to  65 years of age with newly diagnosed Ph+ ALL
were eligible for the CSTIBES02 study if they had an Eastern
Cooperative Oncology Group (ECOG) performance status of 0 to
2, adequate renal and hepatic function (serum creatinine < 2
mg/dL and bilirubin < 2 mg/dL), an adequate cardiac status and a
negative pregnancy test. Patients with serious underlying medical
problems were excluded as were those who had received investi-
gational anti-leukemic therapy within the preceding 7 days.
Females of childbearing potential were required to use an effective
method of contraception. The trial was activated in April 2003 and
was closed for follow-up in September 2008.
Study design and therapy
This was a prospective, non-randomized, phase II trial conduct-
ed by the Spanish PETHEMA (Programa Español de Tratamiento
en Hematología) and GETH (Grupo Español de Trasplante
Hemopoyético) groups. The protocol was reviewed and approved
by the institutional review board of each of the participating cen-
ters and was conducted in accordance with the Declaration of
Helsinki. Patients provided written consent before entering the
study. The trial was registered at http://www.clinicaltrials.gov
with the number NCT00388895.
The treatment schedule is shown in Table 1. Remission induc-
tion therapy consisted of weekly vincristine and daunorubicin,
and daily prednisone and imatinib (400 mg/day from day 1). Bone
marrow aspiration was performed on day 15: patients with a stan-
dard response (≤5% blast cells or hypocellular bone marrow) con-
tinued with the same schedule up to day 28, whereas those with
a slow response (>5% blast cells) received mitoxantrone and
cytarabine together with imatinib (Table 1). Treatment was con-
sidered to have failed in patients who did not attain complete
remission, and these patients were excluded from the study. The
first cycle of consolidation therapy (C1) consisted of high-dose
methotrexate, mercaptopurine, high-dose cytarabine, teniposide
and imatinib (400 mg/day), and the second consolidation cycle
(C2) included vincristine, daunorubicin, dexamethasone,
cyclophosphamide and imatinib (400 mg/day) (Table 1). Full
hematologic recovery, defined as a neutrophil count of at least
1×109/L and a platelet count of at least 50×109/L, was required for
the initiation of each course of consolidation. Central nervous sys-
tem prophylaxis, consisting of intrathecal injections of  methotrex-
ate (15 mg), cytarabine (30 mg) and hydrocortisone (20 mg), was
given during the remission induction cycle (days 1 and 22), C1
(days 1, 28 and 56) and C2 (days 1 and 15). Patients with evidence
of central nervous system leukemia at diagnosis (≥5 leukemic
blasts/µL of cerebrospinal fluid having ensured no contamination
of the sample by peripheral blood) received intrathecal injections
twice a week until two cerebrospinal fluid examinations showed
that the blasts had disappeared. The C2 cycle was not mandatory
if a donor was already available.  
After C2, patients with a HLA-identical donor were submitted
to allogeneic SCT. The remaining patients, as well as those with
medical contraindications to allogeneic SCT, underwent autolo-
gous SCT. In this latter case, hematopoietic stem cell mobilization
was achieved with granulocyte colony-stimulating factor after
recovery from the C2 cycle. Following SCT, all patients were
planned to receive imatinib (400 mg/day) from the time of full
hematologic recovery for at least 1 year if molecular remission per-
sisted. 
The preparative regimen for autologous or allogeneic SCT
(either from an HLA-identical sibling or from an unrelated donor)
consisted of fractionated total body irradiation (total dose 13 Gy,
from day –7 to –4), and cyclophosphamide (60 mg/kg days –3 and
–2). For patients aged over 50 years a non-myeloablative condi-
tioning regimen with fludarabine (30 mg/m2, from day –8 to –4)
and melphalan (70 mg/m2, days –3 and –2) was recommended.
The recommended conditioning regimen for the patients in
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whom unrelated cord blood was the source of hematopoietic stem
cells included tiothepa (5 mg/kg days –7 and –6), fludarabine (50
mg/m2, days –5, -4 and –3), busulphan (3.2 mg/kg in intravenous
infusion days –5, -4 and –3) and thymoglobulin (2 mg/kg days –5,
-4, -3 and –2). 
Dose modifications
For patients aged 60 years or older, the dose of cytarabine in the
induction therapy was reduced to 500 mg/m2 every 12 h, while
the dose of methotrexate in the C1 cycle was reduced to 0.75
g/m2. 
The dose of imatinib could be modified, based on the following
conditions. During the remission induction and consolidation
courses, hematologic toxicity was essentially not considered a rea-
son for reducing the dose of imatinib or suspending treatment
with this tyrosine kinase inhibitor. In cases of grade 3 or 4 non-
hematologic toxicity, administration of imatinib was interrupted
until recovery to grade 1 or better and then resumed at a dose of
400 mg/day. If grade 3 or 4 toxicity recurred after resuming ima-
tinib, the dose was reduced to 300 mg or 200 mg. Imatinib was
not to be interrupted during the interval between induction and
consolidation cycles or between the two consolidation courses or
during the mobilization and collection of hematopoietic stem
cells. The administration of imatinib was, however, suspended 15
days before SCT and resumed after full hematologic recovery had
been achieved. If imatinib-related toxicity or intolerance occurred
after the SCT, the dose could be reduced to 300 mg or 200 mg
before considering permanent discontinuation of the therapy.
Supportive care
Decisions on hospital admissions, prophylaxis and manage-
ment of infections, and transfusions were made in accordance
with specific protocols of each participating hospital. Granulocyte
colony-stimulating factor (5 µg/kg/day, subcutaneously) was
administered to all patients who developed neutropenia following
the induction and consolidation cycles. In cases of autologous or
allogeneic SCT, granulocyte colony-stimulating factor was admin-
istered from day +7 after the transplant until sustained neutrophil
recovery (white cell count >1×109/L) had been achieved.
Evaluation of patients
The primary objectives of this study were to determine the
complete remission rate in this series of patients with Ph+ ALL, the
proportion of patients reaching SCT in first molecular complete
remission and the feasibility and efficacy of imatinib after SCT.
The secondary aims were to assess the toxicity and safety of the
therapy, response duration and survival. Pretreatment evaluations
included clinical history and physical examination, complete
blood count with differential, sequential multiple analysis-12, and
bone marrow aspiration for cytology, flow cytometry and cytoge-
netic studies. Bone marrow aspirates were repeated on day 14
after the start of therapy, at the time of evaluating complete remis-
sion (usually on days 28 to 35 after starting chemotherapy), before
the C2 cycle, before SCT, and every 3 months after SCT. 
Quantitative real-time polymerase chain reaction (RT-PCR)
assays for BCR-ABL were performed on bone marrow and
peripheral blood samples using TaqMan technology in accordance
with the guidelines approved in the Europe Against Cancer
Program.15 The assays were carried out in a central laboratory par-
ticipating in this program. Standard curves were produced for
major and minor BCR-ABL breakpoint variants from 10-fold dilu-
tion series of five different plasmid concentrations (200,000,
20,000, 200, 20 and 2 copies/µL). To minimize variability in the
results due to differences in the efficiency of cDNA synthesis and
RNA integrity among the patients’ samples, the absolute BCR-
ABL copy number was normalized to the expression of the GUS
housekeeping gene, chosen according to the Europe Against
Cancer Program.16 The normalized values of the BCR-ABL copies
in each sample are reported as BCR-ABL copy numbers. All
experiments were carried out in duplicate. At least 105 GUS plas-
mid equivalents were required in a sample to consider a negative
PCR result valid; otherwise, the sample was not useful for mini-
mal residual disease studies. All reactions were performed on an
ABI PRISM 7700 DNA Sequence Detection System (Applied
Biosystems, Foster City, CA, USA). Fluorescence spectra were
continuously monitored and analyzed by the SDS system
(Applied Biosystems, software version 1.9). Samples were collect-
ed at diagnosis, at day 14 of remission induction therapy, at the
Imatinib before and after transplant in Ph+ ALL
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Table 1. Chemotherapy schedule for patients with BCR-ABL-positive
ALL in the CSTIBES02 study.
Drug Dose Route Days
Remission induction
Imatinib 400 mg/d PO 1-14
Vincristine 1.5 mg/m2* IV 1, 8
Daunorubicin 60 mg/m21h IV 1, 8
Prednisone 60 mg/m2 IV or PO 1-14
MTX, AraC, HDC 15, 40, 20 mg/d IT 1
Standard response
Imatinib 400 mg/d PO 15-28
Vincristine 1.5 mg/m2* I 15, 22
Daunorubicin 60 mg/m2 1h IV 15, 22
Prednisone 60 mg/m2 IV or PO 15-28
MTX, AraC, HDC 15, 40, 20 mg/d IT 21
Slow response
Imatinib 400 mg/d PO 15-28
Mitoxantrone 12 mg/m2 IV 15-17
AraC 1g/m2/12h† IV 18, 19
MTX, AraC, HDC 15, 40, 20 mg/d IT 21
Consolidation 1 (C1)
Imatinib 400 mg/d PO 1 until C2
Mercaptopurine 50 mg/m2 PO 1-7, 28-35, 56-63
Methotrexate 1.5 g/m2‡ 24 h IV 1, 28, 56
Teniposide 150 mg/m2/12h IV 14, 42
AraC 500 mg/m2/12h IV 14-15, 42-43
MTX, AraC, HDC 15, 40, 20 mg/d IT 1, 28, 56
Consolidation 2 (C2)
Imatinib 400 mg/d PO 1 until SCT
Dexamethasone 10 mg/m2 IV or PO 1-14
5 mg/m2 IV or Po 15-21
Vincristine 1.5 mg/m2* IV 1, 8, 15
Daunorubicin 30 mg/m2 1h IV 1, 2, 8, 9
Cyclophosphamide 600 mg/m2 IV 1, 15
MTX, AraC, HDC 15, 40, 20 mg/d IT 1, 21
IV: intravenously; PO: per os; IT: intrathecal; AraC, cytarabine; HDC,hydrocortisone;
*Maximum dose 2.0 mg; †AraC 0.5 g/m2 in patients aged 60 years or older. ‡MTX 0.75
g/m2 in patients aged 60 years or older.
time of evaluation of complete remission, following the C1 cycle,
before SCT and every 3 months after SCT. Negative results were
not confirmed by nested PCR. 
Concurrent detection of minimal residual disease (MRD) was
performed by multiparametric flow cytometry (FACScan,
Becton/Dickinson Biosciences, San José, CA, USA) in the same
bone marrow sample and laboratory using quadruple staining, as
previously described.17 Briefly, erythrocyte-lysed whole bone mar-
row samples were stained with an identical panel of four-color
(fluoroscein isothiocyanate, phycoerythrin, peridin cholophyll-
cyanin 5, allophycocyanin) combinations of monoclonal antibod-
ies aimed at the specific identification of blast cells,18 as follows:
CD10/ CD20 / CD19/ CD34, CD10/ CD19/ CD38/ CD34, CD10/
CD34/ CD19/ CD45, CD10/ CD13/ CD19/ CD34, and CD10/
CD33/ CD19/ CD34. All monoclonal antibodies were purchased
from Becton Dickinson. In order to increase the sensitivity of the
analysis, flow cytometric data from follow-up samples was
acquired in two consecutive steps. Briefly, in the first step, all the
cells present in the sample were analyzed and at this point at least
20,000 events/tube were measured. Subsequently, in a second
step, a multiparametric live-gate was used to acquire more specif-
ic data on leukemic cells, which may be present at low frequencies
in the sample. For this purpose, a low to intermediate SSC/ CD19+
and SSC/CD34+ antigen live gate was applied and information
was collected for at least 105 bone marrow nucleated cells. Data
analysis was based on the identification of cells with aberrant phe-
notypic features.18 Either the LYSIS II or Cell-Quest software pro-
gram (Becton Dickinson Biosciences) was used for data acquisi-
tion. The PAINT-A-GATE PRO software program (Becton
Dickinson Biosciences), with a polynomial SSC transformation
function, was used for further data analysis. 
Toxicity was evaluated on the basis of the National Cancer
Institute Expanded Common Toxicity Criteria (NCI-CTC) version
2.0.  Studies on ABL kinase domain mutations were not routinely
performed.
Response criteria
Complete remission was considered to have been achieved
when all the following criteria were fulfilled: less than 5% blasts
in bone marrow, no leukemic blasts in the peripheral blood, recov-
ery of peripheral blood neutrophil counts to at least 1.5×109/L and
platelet counts to at least 100×109/L and no evidence of
extramedullary leukemia. Other defined outcomes were induction
death (if death occurred after starting therapy and without the
patient fulfilling the criteria for complete remission or resistant dis-
ease), resistant disease (if the patient survived the induction treat-
ment period but the leukemia persisted or re-grew) and relapse (if
disease recurred at any site after the  patient had achieved a com-
plete remission). A major molecular response was defined as the
achievement of less than 50 copies of ABL-BCR in the bone mar-
row (as assessed by quantitative RT-PCR), in the presence of cyto-
logical complete remission, no MRD (assessed by flow cytometry
with a threshold of 0.01%) and the hematologic criteria for com-
plete remission. A complete molecular response was defined as
the absence of BCR-ABL copies and no MRD assessed by flow
cytometry with a threshold of 0.001%.
Statistical analysis
Disease-free survival was measured from the date of the com-
plete remission until documented relapse or death in remission
from any cause. Overall survival was measured from the date of
starting therapy until death from any cause. Transplant-related
mortality was defined as death occurring after SCT in relapse-free
patients. Disease-free and overall survival curves were plotted
according to the method of Kaplan and Meier19 and the differences
analyzed by the log-rank test.20 Patients undergoing SCT were not
censored at the time of transplantation. The Statistical Package for
Social Sciences (SPSS) 12.0 software (SPSS, Chicago, IL, USA) was
used for all statistical analyses.
Results
Patients’ characteristics
Between April 2003 and November 2004, 30 patients
with newly diagnosed Ph+ ALL entered the study. The
patients’ characteristics are listed in Table 2. The p190BCR-ABL
transcript (e1a2) was expressed in 23 (80%) of the 30
patients and a p210BCR-ABL transcript (b2a2 or b3a2) in the
remaining seven (20%). The median age of the group was
44 years and there was only one patient under 15 years old
and two over 60 years old. Sixteen (53.3%) of the patients
were male.
Treatment efficacy
Figure 1 shows the progression of the patients along the
trial. Twenty-seven (90%) of the 30 patients achieved a
complete remission. This complete remission rate is higher
than that observed in the ALL93 trial (70%, P=0.045), in
which the same chemotherapy, but without imatinib, was
used. One patient had resistant leukemia and two patients
died in the remission induction period from infections. Of
the 27 patients who achieved a complete remission, 20 had
a standard response already detectable at day 14, while the
other seven had a slow response. One patient was removed
from the study before C1 because of disseminated central
nervous system tuberculosis. Twenty-six patients received
the first consolidation cycle (C1) and 15 the second one
(C2). One patient died after the C1 cycle due to infection.
Four patients relapsed before SCT, two of them after C1
and two after C2. 
Transplantation outcome
SCT (allogeneic, 16; autologous, 5) was performed in 21
out of 27 (78%) patients who achieved a complete remis-
sion. The median time from complete remission to SCT
was 187 days (range, 129 to 297 days). Conditioning regi-
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ECOG performance status, 0/1/2 7/17/6
White blood cell count, ×109/L
Median 18
Range 1-35
Peripheral blood blasts, ×109/L
Median 7
Range 1-23
BCR-ABL transcripts, p190/p210 23/7
*One patient under 15 years, and two over 60 years.
mens included cyclophosphamide and total body irradia-
tion (n=16), and tiothepa, fludarabine, busulphan and thy-
moglobulin in the three patients receiving an unrelated cord
blood transplant, and a reduced intensity regimen with flu-
darabine and melphalan in two additional patients. As
regards the allogeneic transplants, the donor was an HLA
identical sibling for eight patients and an alternative donor
for the other eight patients, including three who received
hematopoietic stem cells from umbilical cord blood.
Engraftment was successful in all patients. Non-relapse
transplant-related deaths occurred in eight patients after
related donor SCT (n=2), after non-myeloablative related
donor SCT (n=2), after matched unrelated donor SCT (n=2)
and after autologous SCT (n=2). The main causes of death
in these patients included early death before hematologic
recovery (n=2), graft-versus-host disease (GVHD) (n=4),
post-transplant lymphoproliferative disorder (n=1) and
pneumococcal pneumonia after complete hematologic
recovery following an autologous SCT (n=1). Five patients
had a relapse in bone marrow (n=4) or in bone marrow and
the central nervous system (n=1) between 5 and 27 months
after SCT (4 allogeneic and 1 autologous).  
Minimal residual disease measurements
Quantitative RT-PCR showed that the bone marrow
contained less than 50 copies of BCR-ABL in 6 out of 29
(21%) evaluable patients on day 14 and in 24 out of 28
(86%) patients at the time of complete remission (Figure 2).
The median BCR-ABL copy number decreased 1 log on day
14 with an additional 2 log reduction at the time of com-
plete remission. In turn, levels of MRD under 0.01%, as
assessed by flow cytometry, were observed in 5 out of 29
(17%) patients on day 14 and in 12 of 28 (43%) evaluable
patients at the end of induction (Figure 3). As in the PCR
study, there was a median 3 log reduction in the level of
MRD during the remission induction period. There was an
additional mean reduction of 2 logs in residual disease
before the onset of C2. Before C2, 11 out of 26 (42%)
patients were PCR negative and 15 out of 26 (58%) cases
were negative for MRD assessed by flow cytometry. Before
SCT, 15 out of 23 (65%) patients were PCR-negative and
14 out of 23 (61%) were negative for MRD assessed by
flow cytometry. No significant reduction was observed in
MRD between the onset of C2 and the time of SCT. After
SCT, 15 out of 19 patients (79%) achieved a complete
molecular response according to the RT-PCR results and 17
out of 19 patients according to the flow cytometry assess-
ment (Figures 2 and 3). All patients in molecular complete
remission before and after SCT according to both assess-
ment techniques (n=6) remained in continuous complete
remission at last follow-up. Conversely, detection of less
than a major response before or after SCT by either of the
two techniques was invariably associated with relapse.
Post-SCT major response was associated with relapse only
if PCR and flow cytometry results were concordant. A one
log increase in MRD both before and after SCT was predic-
tive of relapse, whichever technique had detected the incre-
ment. Among patients undergoing an autologous SCT only
one was MRD-positive before the procedure and relapsed
early afterwards; none of the other four relapsed although
two died of other causes.
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Figure 1. Flow chart of the patients included in the trial. MUD:
matched unrelated donor; RIC: reduced intensity conditioning; UCB:
unrelated cord blood; TRM transplant-related mortality.
Figure 2. Progression of MRD of individuals assessed by RT-PCR.
Values are expressed on a logarithmic scale and negative values
set at 0. Boxes represent medians and quartiles; dots represent
patients with outlier values. Rounded asterisks represent values for
individual patients who relapsed after that control. Out of eight
patients in sustained complete remission only one had a positive
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Imatinib after stem cell transplantation
Imatinib was started following SCT in 13 out of 21
patients (62%). The median time from SCT to initiation of
imatinib therapy was 3.9 months. Four out of five patients
who had undergone autologous SCT were able to start
imatinib maintenance therapy, which was continued up to
the last control (at 40 and 60 months) in two patients or
death in the other two. The remaining patient did not start
imatinib therapy because of persistent severe thrombocy-
topenia after the transplant, followed by early post-SCT
relapse. The main reasons for not initiating imatinib among
patients who underwent allogeneic SCT were early trans-
plant-related mortality (n=4, including the patient with
post-transplant lymphoproliferative disease), severe GVHD
(n=1) and the patients’ decision (n=2). The median time on
imatinib therapy for the remaining nine patients who
underwent allogeneic SCT was 9 months (range, 1 to 27).
The post-SCT dose of imatinib was reduced to 200 mg in
three patients (two were able to continue imatinib treat-
ment to last control and another patient had to discontinue
treatment). Imatinib therapy was interrupted due to relapse
(n=3), severe chronic GVHD (n=2), grade 3-4 toxicity (n=2,
hematologic in one patient and gastrointestinal in the
other), non-relapse death (n=1) and  patient’s choice (n=1)
after 24 month of continuous imatinib treatment. 
Survival 
Nine patients remain alive after 3 years of follow-up,
eight with a molecular complete response and one with
molecular relapse. After a median follow-up of 4.1 years
(range, 3.9-4.8), the median disease-free and overall sur-
vival were 1.5 years and 1.7 years, respectively. The proba-
bilities of disease-free and overall survival were 30% (95%
CI 16% to 45%) and 30% (95%CI 15% to 45%), respec-
tively.  (Figure 4). The survival of these patients was signif-
icantly better than that of an historical cohort of 37 patients
included in the ALL93 trial in which patients were treated
with chemotherapy and SCT but not imatinib (Online
Supplementary Figure S1). 
Toxicity
Table 3 shows the hematologic toxicity that occurred
during the induction and consolidation periods. Grade III-
IV neutropenia was observed in almost all induction cycles,
especially in patients receiving intensified induction. The
frequency and duration of severe neutropenia was lower
after the C1 and C2 cycles. The frequency of severe throm-
bocytopenia throughout the study was low and no cases of
severe thrombocytopenia were observed in the C2 cycle.
Table 4 shows the cases of grade III-IV non-hematologic
toxicity. The most frequent adverse events were infections,
especially bacterial one, followed by hepatic and gastroin-
testinal toxicity. Other frequent grade I-II toxicities were
hepatic adverse events, fluid retention, mucositis and wast-
ing syndrome. 
No major toxic events were observed during the mobi-
lization of peripheral blood hematopioetic stem cells, either
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Figure 3. Progression of MRD of individuals as assessed by flow
cytometry. Values are expressed on a logaritmic scale and negative
values set at minus 4. Boxes represent medians and quartiles; dots
represent patients with outlier values. Rounded asterisks represent
values for individual patients who relapsed after that control. Out of
eight patients in sustained complete remission only one had posi-
tive flow cytometry in a pre-SCT evaluation and none was positive in
any post-SCT controls. 
Figure 4. Probabilities of overall survival (A) and disease-free survival
(B) of the patients included in the CSTIBES02 trial. Black dots in fig-
ures A and B indicate patients alive and alive in complete remission,
respectively.
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for autologous SCT (n=5) or as a back-up prior to an unre-
lated donor or umbilical cord blood SCT (n=8). During this
period the patients continued on imatinib therapy and the
collection of hematopoietic stem cells was adequate in all
cases.
Interruption of post-SCT imatinib maintenance therapy
was directly associated with imatinib in two out of ten
patients (one each with grade III gastrointestinal and hema-
tologic toxicity) and a likely association with imatinib and
other drugs was established in another case (microangio-
pathic thrombocytopenia). No other grade III or higher tox-
icity attributed to imatinib was recorded.
Discussion 
The results of this study confirm that imatinib is an effec-
tive first-line treatment for de novo adult Ph+ ALL when
given concurrently with chemotherapy and allows SCT to
be performed in a substantial proportion of patients in
major or complete molecular remission. However, in the
present trial prophylactic imatinib could not be given as
scheduled after SCT in a considerable proportion of
patients, mainly because of transplant-related events.
Imatinib-specific toxicity was not an issue for most patients
and, particularly in the setting of autologous SCT, the tyro-
sine kinase inhibitor could be administered safely for a pro-
longed period.
As occurred in other contemporary trials, combining
chemotherapy and imatinib (in concurrent or intermittent
schedules) provided better results in terms of  cytologic and
molecular complete responses,3-8,21 time to hematologic
response and survival than those in historical controls treat-
ed with chemotherapy without imatinib.22-24 It is of note
that the clearance of MRD was mainly observed during the
induction and the first consolidation cycle (C1), with no
further decrease thereafter. The fact that two out of the
four patients in the present study who relapsed before SCT
did so after the C2 cycle raises the question of whether an
earlier transplant would have avoided such relapses. Both
flow cytometric and molecular biology detection of MRD
appeared to be highly predictive of both pre-SCT relapse (4
out of 8 patients relapsing before SCT when MRD > 0.01%
after C1) and post-SCT relapse (5 out of 5 relapsed at any
level of detectable MRD) 
As a result of an improved complete remission rate, 50%
to 86% of patients with Ph+ ALL were able to undergo allo-
geneic SCT in first complete remission in several trials com-
bining imatinib and intensive chemotherapy.3-5,21 We used a
relatively low dose of imatinib (400 mg/day) to ensure con-
tinuous treatment during initial therapy, obtaining similar
short-term results (complete remission rate, molecular
remission rate at the end of induction, and proportion of
cases submitted to allogeneic SCT in a MRD negative sta-
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Table 3. Hematologic toxicities of concurrent chemotherapy and ima-
tinib mesylate in induction and post-induction courses.
Grade III Grade IV Duration in days
N (%) N (%) Median (range)
Days 1 to 14 of induction
Neutropenia 2 (7%) 23 (77%) 8 (1-14)
Thrombocytopenia 2 (7%) 13 (43%) 4 (1-14) 
Days 15 to 28 of standard induction
Neutropenia 0 18 (90%) 14 (2-18)
Thrombocytopenia 1 (5%) 5 (25%) 8 (2-14)
Days 15 to 28 of intensified induction
Neutropenia 0 9 (100%) 14 (7-15)
Thrombocytopenia 1 (11%) 7 (78%) 5 (1-11) 
Consolidation 1*
Neutropenia 0 16 (62%) 4 (1- 23)
Thrombocytopenia 0 10 (38%) I 4 (1-18)
Consolidation 2*
Neutropenia 0 5 (34%) 7 (5-7) 
Thrombocytopenia 0 0
*Neutropenia and thrombocytopenia present for intermittent periods.Figures repre-
sent overall duration for the sum of episodes.
Table 4. Non-hematologic, grade III and IV toxicities of concurrent
chemotherapy and imatinib mesylate in induction and post-induction
courses*. 
Parameter I-1 I-2std I-2int C1 C2
N=30 N=20 N=9 N=26 N=14 
Infections 11 (37) 6 (30) 8 (89) 5 (19) 1 (7)
Bacterial 9 5 6 4 1
Fungal/presumed fungal 0 0 1 0 0
Herpetic 1 0 0 1 0
Pneumonia 1 0 1 0 0
Sepsis 1 1 1 1 0
Catheter-related 0 0 0 2 1
Other 1 1 0 0 0
Cardiovascular 1 (3) 3 (15) 2 (22) 2 (8) 0
Fluid retention 1 2 1 1 0
Arrhythmia / syncope 0 0 0 0 0
Deep venous thrombosis 0 1 1 1 0
Hepatic 2 (6) 3 (15) 0 2 (8) 0 
Increase in bilirubin 1 3 0 2 0
Increase in transaminases 2 0 0 1 0
Neuromuscular 1 (3) 2 (10) 0 3 (12) 0
Fatigue 1 2 0 0 0
Peripheral neuropathy 0 1 0 1 1
Headache 0 1 0 3 0
Bone pain 1 0 0 0 0
Myalgia 0 2 1 1 0
Gastrointestinal 1 (3) 3 (15) 3 (33) 3 (12) 0
Stomatitis 1 2 1 2 0
Constipation 1 1 1 0 0
Diarrhea 0 0 0 0 0
Nausea 1 0 2 1 0
Ileus 1 1 1 1 0
Renal 3 (10) 2 (10) 1 (11) 1 (4) 0
Increase in creatinine 1 1 0 0 0
Elecrolytic imbalance 2 1 1 1 0
Results expressed as number (%). I-1: induction,days 1-14. I-2std: induction,days 15-
28 after standard response. I-2int: induction,days 15-28 if intensification with mitox-
antrone and cytarabine administered.C1: consolidation 1.C2: consolidation 2.
*According to occurrence by patient and cycle, some patients experienced more than
one event.
tus) to those of contemporary trials in which imatinib was
given at a dose of 600 mg/day. 
No definitive consensus has been reached on the need to
systematically perform allogeneic SCT in patients with a
good molecular response.9 In our study, SCT (allogeneic
when possible) was scheduled for all patients who
achieved complete remission and was actually performed
in 74% of them. It is of note that 65% or 61% (PCR or flow
cytometry) of the patients in our series were in complete
molecular remission at the time of SCT. There is evidence
that a good quality remission before SCT is associated with
a lower probability of post-transplant relapse.25
Despite encouraging short-term results, relapses are
observed in  a very significant proportion of patients treat-
ed with the combination of imatinib and chemotherapy,
even after allogeneic SCT, resulting in  a decrease in the
probability of survival down to 30%-50%10,11 in cohorts
with an extended follow-up, as occurred in the present
trial, which is one with the longest follow-up reported to
date. The occurrence of relapses after SCT provides the
rationale for evaluating the usefulness of ‘maintenance’
therapy. There is evidence suggesting that pre-SCT treat-
ment with imatinib does not have detrimental effects on
engraftment, the occurrence and severity of GVHD, or on
transplant-related organ toxicity. Uncontrolled studies have
shown that imatinib can also be safely administered early
after myeloablative allogeneic SCT at a dose intensity com-
parable to that used in primary therapy,13,29 and there is pre-
liminary evidence that imatinib can also be administered
safely after autologous SCT.30 In a study by Wassmann et
al.,26 half of the patients with Ph+ ALL who received ima-
tinib because they had MRD after SCT experienced pro-
longed disease-free survival, which could be anticipated by
the rapid achievement of molecular complete remission.
This makes imatinib a good candidate for maintenance
therapy after SCT, with the objective of preventing relaps-
es, although the need for systematic administration of ima-
tinib after allogeneic SCT has not been adequately
addressed yet. 
An ongoing randomized trial by Wassmann et al.14 is
comparing systematic versus MRD-triggered administration
of imatinib after SCT: the preliminary results show a low
rate of relapses in both arms, suggesting that the adminis-
tration of imatinib early after molecular relapse is equally
effective as the systematic administration of the drug as
long as close molecular follow-up (i.e. every 3 weeks) of the
patients after SCT is ensured. However, imatinib was dis-
continued in 48% of the cases, mostly because of gastroin-
testinal toxicity and GVHD. The impact of allogeneic SCT
toxicity was even more striking in the present trial,
accounting for a significant proportion of non-relapse mor-
tality and significantly limiting post-SCT exposure to ima-
tinib. The relatively high transplant-related mortality may
explain the slightly lower survival observed in our study in
comparison with that of other similar trials.3-8,21
Given the frequency of ABL domain mutations in
young27 and elderly28 patients with Ph+ ALL at diagnosis,
second generation tyrosine kinase inhibitors (dasatinib,
nilotinib) may be alternative candidates for prophylactic
post-SCT treatment. Although ABL mutation studies were
not performed in the present trial, our results suggest that
the main issue in the post-SCT setting is tolerance to treat-
ment rather than the emergence of resistant clones. 
Inferences on the influence of imatinib on transplant-
related mortality cannot be made from the results of our
trial, although such an influence is unlikely. Imatinib was
well tolerated during induction and consolidation and after
SCT. Early transplant-related mortality and GVHD were
the major causes of inability to start  or continue post-trans-
plant imatinib maintenance therapy. In fact, exposure to
imatinib was minimal in a substantial proportion of
patients submitted to allogeneic SCT mainly because of
transplant-related events. The heterogeneous circum-
stances of the patients undergoing SCT, particularly differ-
ences in MRD status, the different sources of stem cells
used, and the variety in post-SCT complications, are con-
siderable limitations to the interpretation of results.
Nevertheless, interruption of imatinib maintenance thera-
py because of toxicity of the drug was rare, with complica-
tions of the allogeneic SCT being the main cause of ima-
tinib suspension. In our trial the two patients with the
longest exposure to imatinib had undergone autologous
SCT. In this regard, lymphocyte-depleted allogeneic SCT
or even autologous SCT appears to be a sensible alternative
if imatinib maintenance therapy is to be attempted.
Whether such maintenance treatment is capable of com-
pensating for a weak graft-versus-leukemia effect of an
undepleted graft remains an unresolved question that can
only be answered by specifically designed trials. The signif-
icant proportion of patients obtaining molecular remission
before SCT and the greater possibility of maintenance ima-
tinib therapy in the patients in our trial would argue in
favor of such strategies. Unfortunately, too few patients
underwent autologous SCT in our trial to enable strong
conclusions to be drawn. 
In summary, our trial confirms the efficacy of therapy
programs combining intensive chemotherapy, imatinib
and SCT. However, we have shown that the systematic
administration of imatinib early after allogeneic SCT is
limited by the occurrence of transplant-related events.
Even when imatinib is given, discontinuation is frequent,
again due to transplant-related events rather than to the
inherent toxicity of the drug. These factors should be
taken into account when planning to give maintenance
therapy with imatinib or other tyrosine kinase inhibitors,
either alone or in combination, after allogeneic SCT. An
autologous SCT might be an adequate alternative
approach, which would be worth exploring in specifical-
ly designed trials.
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